Grace Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Grace Therapeutics, Inc. (GRCE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-18.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2026-06-18
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2026-03-31 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2025-12-31 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2025-09-30 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2025-06-30 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2026 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2024 was $1.63M.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2023 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $0.00 derived: sum of 2 quarters · filed 2026-06-18 | $0.00 derived: sum of 3 quarters · filed 2026-06-18 | $0.00 10-K · filed 2026-06-18 | |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-Q · filed 2026-02-12 | $0.00 derived: sum of 4 quarters · filed 2026-06-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 3 quarters · filed 2026-06-18 | $0.00 derived: sum of 4 quarters · filed 2026-06-18 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 2 quarters · filed 2026-06-18 | $0.00 derived: sum of 3 quarters · filed 2026-06-18 | $0.00 derived: sum of 4 quarters · filed 2026-06-18 | |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $0.00 derived: sum of 2 quarters · filed 2026-06-18 | $0.00 derived: sum of 3 quarters · filed 2026-06-18 | $0.00 10-K · filed 2026-06-18 | |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-Q · filed 2026-02-12 | $0.00 derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 3 quarters · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 2 quarters · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | $1.63M 10-K · filed 2025-06-23 | ||
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $1.63M 10-Q · filed 2025-02-13 | |||
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-13 | ||||
| 2023-09-25 | $1.63M 10-Q · filed 2025-11-13 | ||||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $0.00 10-K · filed 2024-06-21 | |||
| 2022-12-31 | $0.00 10-Q · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |